				Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	i
Substitute for form 1449A/PTO				COMPLETE IF KNOWN	
INFORMATION	DISC	LOSURE	Application Number	10/706,695	
QTAPEMENT R	V A DDI	ICANT	Filing Date	November 12, 2003	
STATEMENT	IAIII	LICANI	First Named Inventor	Joseph L. Duffy et al.	
8 200 2			Group Art Unit		
(use as many snee	us as nec	essary)	Examiner Name	·	
FINARK	of	5	Attorney Docket Number	21277	
	INFORMATION STATEMENT B	INFORMATION DISCI	STATEMENT BY APPLICANT	INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date First Named Inventor Group Art Unit Examiner Name	Substitute for form 1449APTO INFORMATION DISCLOSURE Application Number 10/706,695 Filing Date November 12, 2003 First Named Inventor Joseph L. Duffy et al. Group Art Unit Examiner Name

			U.S. PA	TENT DOCUMENTS	
		U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
4		5,776,954		Stephen E. de Laszlo, et al.	07/07/1998
2	2	4,359,474		Paul L. Anderson, et al.	11/16/1982
3	3	4,567,196		Michel Wierzbicki	01/28/1986
4	;	3,953,468		William J. Wechter, et al.	04/27/1976
5	5	4,608,384		Michael Wierzbicki, et al.	08/26/1986
~~	5	4,831,013		John E. Francis	05/16/1989
\top					
T					
Т					
1					****
\top					
\top					
7					
7					
\top			1		
\top			_	,	
\neg					
	C-1	No. C-1 2 3 4 5 5	Number C-1 5,776,954 2 4,359,474 3 4,567,196 4 3,953,468 5 4,608,384	Cite No.	Cite No. Number Stind Name of Patentee or Applicant of Cited Document

				FOREIGN P	ATEN	T DOCUMENTS	
Exam			Foreign Patent Document King		Kind	Name of Patentee or Applicant	Date of Publication of Cited Document
bitia	s*	No.	Office		Code (if.known)		MM-DD-YYYY
5	<i>∨</i>	7	PCT	WO 00/69810		NOVO NORDISK A/S & AGOURON PHARMACEUTICALS, INC.	11/23/2000
		8	PCT	WO 00/39088		NOVO NORDISK A/S & AGOURON PHARMACEUTICALS, INC.	07/06/2000
		9	PCT	WO 99/01423corrected version		NOVO NORDISK A/S & ALANEX CORPORATION	01/14/1999
		10	PCT	WO 99/01423		NOVO NORDISK A/S & ALANEX CORPORATION	01/14/1999
		11	PCT	WO 98/04528 A2		BAYER CORPORATION & BAYER AKTIENGESELLSCHAFT	02/05/1998
		12	PCT	WO 98/04528 A3		BAYER CORPORATION & BAYER AKTIENGESELLSCHAFT	02/05/1998
		13	PCT	WO 99/22108		MERCK & CO., INC.	05/28/1998
		14	PCT	WO 99/22109		MERCK & CO., INC.	05/28/1998
		15	PCT	WO 97/16442		MERCK & CO., INC.	05/09/1997
51	$\stackrel{\sim}{}$	16	PCT	WO 98/21957		MERCK & CO., INC.	05/28/1998

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include co of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc.,

	•				Patent and Trademark Office; U.S DEPARTMENT OF COMMERC	Ë
	Substitute for form 1449A/PTO				COMPLETE IF KNOWN	
	INFORMATION	DIS	CLOSURE	Application Number	10/706,695	
	SOATEMENT BY	7 A D	DI ICANT	Filing Date	November 12, 2003	
		- ALI	LICANI	First Named Inventor	Joseph L. Duffy, et al.	
	FEB 0 9 2004 (use as many speeds			Group Art Unit		
		s as n	ecessary)	Examiner Name		
She	et TRAUEURE	of	5	Attorney Docket Number	21277	_

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY					
				,						
	·									
	;. 		· -		·					
		V. N			·					

				FOREIGN PA	TEN	T DOCUMENTS	
Examiner Cite			Foreign Patent Document			Date of Publication of	
	Examiner Ci Initials* N		Office		Kind Code (known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
1		17	PCT	WO 99/46267		NOVO NORDISK A/S	09/16/1999
Ĺ		18	PCT	WO 99/32448		AMGEN, INC.	07/01/1999
		19	PCT	WO 99/32448 corrected version		AMGEN, INC.	07/01/1998
		20	PCT	WO 02/18335		YAMANOUCHI PHARMACEUTICAL CO., LTD.	03/07/2002
		21	PCT	WO 01/58890		ASTRAZENECA AB	08/16/2001
		22	PCT	WO 01/46165		NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	06/28/2001
		23	PCT	WO 01/44226		PROTHERICS MOLECULAR DESIGN LIMITED	06/21/2001
		24	PCT	WO 01/40223 A2		NOVARTIS AG	06/07/2001
		25	PCT	WO 01/40223 A3		NOVARTIS AG	06/07/2001
ζ	5	26	PCT	WO 01/36415		NOVARTIS AG	05/25/2001

Examiner Signature G. Way Date Considered 5/18/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Form* (ID

•		Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE
* Substitute for form 1449A/PTO		COMPLETE IF KNOWN .
INFORMATION DISCLOSURE	Application Number	10/706,695
O I PLEATEMENT BY A DRI ICANT	Filing Date	November 12, 2003
[<u>6</u>]	First Named Inventor	Joseph L. Duffy, et al.
	Group Art Unit	
	Examiner Name	
3 of 5	Attorney Docket Number	21277
	INFORMATION DISCLOSURE OF STATEMENT BY APPLICANT B 0 9 2004 & (useus many sheets as necessary)	Substitute for form 1449APTO INFORMATION DISCLOSURE Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

		U	.S. P.	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code known)		Date of Publication of Cited Document MM-DD-YYYY
:					
					:
		· ·			

				FORE	IGN PATEN	T DOCUMENTS	
		Cite No.	Office	Foreign Patent Docume Number	nt Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
ζ	U -	27	PCT	WO 01/32632 A2	(if known)	ELI LILLY AND COMPANY	MM-DD-YYYY 05/10/2001
	Ī	28	PCT	WO 01/32632 A3		ELI LILLY AND COMPANY	05/10/2001
		29	EP	0 263 071 A1		CIBA-GEIGY AG	04/06/1988
		30	EP	0 263 071 B1		CIBA-GEIGY AG	04/06/1988
		31	EP	0 253 259 A2		BAYER AG	01/20/1988
		32	EP	0 253 259 A3		BAYER AG	01/20/1988
		33	EP	0 193 885 A1		BASF	09/10/1986
		34	EP	0 193 885 B1		BASF	09/10/1986
I		35	EP	0 202 538 A1		BAYER AG	11/26/1986
ζ,	~	36	EP	0 202 538 B1		BAYER AG	11/26/1986

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Forder), Merch & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO		Patent and Tradentark Office; U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/701,186
STATEMENT BY APPLICANT	Filing Date	November 4, 2003
	First Named Inventor	Joseph L. Duffy, et al.
(use as mostly sheets as necessary)	Group Art Unit	
	Examiner Name	
Sheet 4 of 5	Attorney Docket Number	21167

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY					
	-				,					
			-							
	;		-		· ·					
	-									
	·									
			+		·					

Foreign Patent Document						
examin nitials*		Office		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
50	~ 37	EP	0 217 748 A2	•	CIBA-GEIGY	04/08/1987
	38	EP	0 217 748 B1		CIBA-GEIGY	04/08/1987
	39	FR	2 565 981		ADIR	12/20/1985
	40	FR	2 564 467		ADIR	11/22/1985
	41	DE	35 29 247 A1		BAYER AG	11/20/1986
	42	DE	36 24 304 A1		BAYER AG	01/28/1986
	43	DE	41 19 767 A1		ARZNEIMITTELWERK DRESDEN GmbH	02/15/2002
	44	DE	35 07 421 A1		BASF AG	09/04/1986
50	45	JР	2002-50169		FUJI PHOTO FILM CO., LTD.	02/15/2002

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Forder), Merck & Co., Inc., 09/05/2003

				Paters and Trademark Office; U.S DEPARTMENT OF COMMERCE	
ubstitute for form 1449B/PTO			COMPLETE IF KNOWN		
NPORMATION:	DISCI	LOSURE	Application Number	10/706,695	
TATEMENT BY	A DDI	ICANT	Filing Date	November 12, 2003	
O 9 2004	AIII	JCANI	First Named Inventor	Joseph L. Duffy et al.	
£7			Group Art Unit		
TRADENT SHEETS	as nece	essary)	Examiner Name		
5	of	5	Attorney Docket Number	21277	
	TATEMENT BY	TATEMENT BY APPI	TATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	

			NON PATENT LITERATURE DOCUMENTS						
Examiner Cite Initials* No.			Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
5.	\ \	16	Guillon, Jean, et al., "Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonist", Eur. J. Med. Chem, 33, pp. 293-308 (1998)						
	4	1 7	Petersen, K. F., et al., "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", <i>Diabetologia</i> , 44, pp. 2018-2024 (2001)						
	4	18	Ladouceur, Gaetan, H., et al.,"Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists", Bioorganic & Medicinal Chemistry Letters, 12, pp. 461-464 (2002)						
	4	19 .	Cascieri, Margaret, A., "Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor, <i>The Journal of Biological Chemistry</i> , Vol. 274, Issue of March 26, pp. 8694-8697 (1999)						
	5	50	de Laszlo, Stephen, E., "Potent, Orally Absorbed Glucagon Receptor Antagonists", Bioorganic & Medicinal Chemistry Letters, 9, pp. 641-646 (1999)						
	5	51	Madsen, Peter, et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human glucagon Receptor Antagonists", J. Med Chem, 41, pp. 5150-5157 (1998)						
	5	52	Ling, Anthony, et al., "Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists", <i>J. Med. Chem</i> , 44, pp. 3141-3149 (2001)						
	5	53	Ling, Anthony, et al., "Human Glucagon Receptor Antagonists Based on Alkylidine Hydrazides", Bioorganic & Medicinal Chemistry Letters, 12, pp. 663-666 (2002)						
	5	54	Collins, Judith, L., "CP-99,711: A Non-Peptide Glucagon Receptor Antagonist", Bioorganic & Medicinal Chemistry Letters, Vol. 2, No. 9, pp. 915-918 (1992)						
	5	55	Parker, Janice, C., "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and human Hepatocytes", <i>Diabetes</i> , Vol. 49, pp. 2079-2086 (December 2000)						
	5	56	Connell, Richard, D., "Glucagon antagonists for the treatment of Type 2 diabetes", Expert Opinion on Therapeutic patents, 9(6), pp. 701-709 (1999)						
5 l	/_5	i7	Madsen, P., et al., "Advances in Non-Peptide Glucagon Receptor Antagonists", Current Pharmaceutical Design, 5, pp. 683-691 (1999)						
-	\top								

Examiner Signature	5.1	~ meg	Date Considered	51	18/	07

^{*}Examiner: Initial if reference considered, whether or not citation is in obnformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next-communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003